Corcept Therapeutics Overview
- Founded
-
1998

- Status
-
Public
- Employees
-
238

- Stock Symbol
-
CORT

- Share Price
-
$27.46
- (As of Thursday Closing)
Corcept Therapeutics General Information
Description
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Contact Information
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 149 Commonwealth Drive
- Menlo Park, CA 94025
- United States
+1 (650) 000-0000
Corcept Therapeutics Stock Performance
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$27.46 | $27.01 | $15.82 - $29.93 | $2.94B | 107M | 703K | $1.01 |
Corcept Therapeutics Financials Summary
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 2,183,931 | 1,925,663 | 2,613,322 | 1,151,922 |
Revenue | 392,027 | 365,978 | 353,874 | 306,486 |
EBITDA | 134,135 | 127,544 | 130,439 | 113,777 |
Net Income | 112,733 | 112,512 | 106,011 | 94,181 |
Total Assets | 496,364 | 423,756 | 571,731 | 412,312 |
Total Debt | 2,264 | 526 | 2,551 | 3,461 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Corcept Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Corcept Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medica
Pharmaceuticals
Menlo Park, CA
238
As of 2021
00000
00000000000
00000
Corcept Therapeutics Competitors (25)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
00000000 000000000 | Formerly VC-backed | Ann Arbor, MI | 000 | 00000 | 00000000000 | 00000 |
000000 00000000000 | Formerly VC-backed | Boston, MA | 00 | 00000 | 000000000 | 00000 |
000000000 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
00000000 000000000 | Formerly VC-backed | Switzerland | 00 | 00000 | 000000000 | 00000 |
Corcept Therapeutics Patents
Corcept Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210369689-A1 | Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c9 substrates | Pending | 27-May-2020 | 0000000000 | |
US-20220184061-A1 | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 | Pending | 27-May-2020 | 00000000000 | |
US-20210369690-A1 | Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c8 substrates | Pending | 27-May-2020 | 00000000000 | |
US-20210369700-A1 | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 | Granted | 27-May-2020 | 000000000 | |
US-11285145-B2 | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 | Active | 27-May-2020 | A61P35/00 | 00 |
Corcept Therapeutics Executive Team (12)
Corcept Therapeutics Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
Daniel Swisher Jr. | Self | Board Member | 000 0000 |
David Mahoney | Self | Board Member | 000 0000 |
George Baker Jr. | Corcept Therapeutics | Board Member | 000 0000 |
Gillian Cannon Ph.D | Self | Board Member | 000 0000 |
Gregg Alton JD | Self | Board Member | 000 0000 |